Pharma BD Deal Intelligence
An all-cash acquisition that let Merck KGaA build a rare-tumor franchise around two FDA-approved products—Ogsiveo for desmoid tumors and Gomekli for NF1 plexiform neurofibromas—for $3.4 billion enterprise value. The deal, Merck KGaA's largest healthcare acquisition in nearly two decades, was expected to be immediately revenue-accretive and EPS-accretive by 2027.
Merck KGaA closes in on SpringWorks deal at $3.5B price point. The Endpoints article reported on the late-stage M&A negotiations between the German pharma and…
Germany's Merck KGaA said Monday it would buy SpringWorks Therapeutics for $47 a share in cash, a deal with an equity value of nearly $4 billion. The…
Merck KGaA completes $3.4B SpringWorks acquisition gaining two first-in-class rare oncology drugs; largest healthcare deal by the company in nearly 20 years
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Merck KGaA, Darmstadt, Germany acquired SpringWorks Therapeutics (Nasdaq: SWTX) in an all-cash transaction at $47.00 per share, for an equity value of approximately $3.9 billion and an enterprise value of about $3.4 billion (~EUR 3.0 billion) net of SpringWorks' cash. Announced April 28, 2025 and completed July 1, 2025 following regulatory clearances, it is Merck KGaA's largest Healthcare-sector acquisition in nearly two decades. The deal builds a rare-tumor franchise around two FDA-approved commercial products: Ogsiveo (nirogacestat), the first-in-disease systemic therapy for adults with progressing desmoid tumors, and Gomekli (mirdametinib), the first and only FDA-approved therapy for adult and pediatric NF1 patients with symptomatic plexiform neurofibromas not amenable to complete resection. The acquisition is expected to contribute to revenue immediately and to be accretive to EPS pre by 2027. Both assets advanced in the EU around closing: CHMP adopted positive opinions for mirdametinib (May 2025) and nirogacestat (June 2025).
100K US cases/yr · $800M US NF1 Rx Market
NF1 is a genetic disorder causing tumors on nerve tissue. Plexiform neurofibromas affect ~30-50% of NF1 patients and can cause significant disfigurement and functional impairment. Gomekli is the only FDA-approved treatment for symptomatic, inoperable plexiform neurofibromas.
Gomekli (mirdametinib) is the only approved MEK inhibitor for NF1 plexiform neurofibromas. Selumetinib (Koselugo, AstraZeneca) is approved for pediatric NF1 but Gomekli serves the broader age range including adults.
2K US cases/yr · $500M US Desmoid Tumor Rx
Desmoid tumors are rare, locally aggressive connective tissue tumors that can cause significant morbidity. Prior to nirogacestat, no systemic therapy was specifically approved, and treatment relied on surgery, NSAIDs, and off-label chemotherapy.
Ogsiveo (nirogacestat) is the first and only FDA-approved therapy specifically for desmoid tumors. Gamma-secretase inhibitor mechanism with strong clinical data from DeFi trial. Limited direct competition in this niche indication.
Merck KGaA completed $3.4B acquisition of SpringWorks Therapeutics, gaining Ogsiveo (nirogacestat) for desmoid tumors and rare disease/oncology pipeline.
Ogsiveo already FDA-approved at acquisition. Merck KGaA gains immediate commercial rare disease asset plus pipeline. Too early to assess full integration.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck KGaA / SpringWorks Therapeutics (this deal) | 2025 | $3.4B | 72 |
| Merck KGaA / Millipore Corporation | 2010 | $7.2B | 88 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Merck KGaA / Versum Materials | 2019 | $5.8B | 80 |
| Merck KGaA / Serono SA | 2006 | $13.2B | 74 |
| Merck KGaA / Threshold Pharmaceuticals, Inc. | 2012 | $550M | — |
| Merck KGaA / Debiopharm | 2021 | $1.1B | — |
← Browse all deals · How we score deals
More: 2025 deals · Merck KGaA deals · Oncology deals